Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.
Akari Therapeutics plc (NASDAQ: AKTX) is an oncology biotechnology company whose news flow centers on the development of its PH1-based antibody–drug conjugates (ADCs). Company updates frequently highlight progress with its lead Trop2-targeting ADC, AKTX-101, and the broader PH1 spliceosome-modulating payload platform designed to disrupt RNA splicing in cancer cells and activate immune responses.
Investors following AKTX news can expect regular announcements on preclinical data, particularly in hard-to-treat solid tumors such as KRAS-mutant pancreatic ductal adenocarcinoma, urothelial (bladder) cancer, and gastric cancer. Akari’s releases often describe new efficacy and safety findings for AKTX-101, including comparisons with ADCs that use traditional payloads and exploratory work on synergy with checkpoint inhibitors.
Another recurring news theme is platform and pipeline development. Akari reports on the evolution of its ADC discovery platform, the advancement of additional candidates like AKTX-102 for GI and lung cancers, and scientific engagement through conference presentations and virtual investor segments such as its “CEO Corner” and “What This Means” features.
On the corporate side, Akari’s news includes financing transactions, such as registered direct offerings, private placements with warrants, and note exchanges that the company states are intended to fund research and development, working capital, and general corporate purposes. Updates on manufacturing partnerships, including GMP manufacturing of AKTX-101 with WuXi XDC, and disclosures related to Nasdaq listing requirements also appear in its news stream.
For readers tracking oncology innovation and early-stage ADC pipelines, the AKTX news page offers a focused view of how Akari is progressing its PH1 payload technology, preparing for potential clinical trials, and managing the capital and governance steps that support its development plans.
Akari Therapeutics (Nasdaq: AKTX) CEO Abizer Gaslightwala joined a Virtual Investor “What This Means” interview on Feb. 11, 2026 to discuss the company’s expanded ADC pipeline, a recent patent filing, and the introduction of second ADC candidate AKTX-102 targeting CEACAM5 tumors.
The segment reviewed the scalability of Akari’s PH1-powered ADC platform, the company’s differentiated CEACAM5 antibody construct, execution priorities for lead program AKTX-101 as it advances toward IND and CTA submissions, and the strategic role of a growing patent estate to support partnering and long-term value creation.
Akari Therapeutics (Nasdaq: AKTX) will present a live video webcast on Tuesday, February 10, 2026 at 1:00 PM EST as part of Webull Financial’s Corporate Connect Webinar Series.
CEO Abizer Gaslightwala will provide a corporate overview of Akari’s ADC platform, the proprietary PH1 spliceosome‑modulating payload, lead program AKTX‑101 (Trop2‑targeting ADC), IND‑enabling activities toward a first‑in‑human trial in late 2026 or early 2027, and a brief update on AKTX‑102.
Akari Therapeutics (NASDAQ: AKTX) filed U.S. provisional patent No. 63/958,508 for AKTX-102, a CEACAM5-targeted ADC that pairs a novel antibody construct with Akari’s PH1 spliceosome payload.
The filing claims composition-of-matter protection for antibody design and ADC constructs and expands Akari’s PH1 patent family. CEACAM5 expression cited: 80–90% of gastrointestinal cancers, ~30% bladder, 25% lung adenocarcinomas, up to 50% luminal A breast. Akari plans IND-enabling work for AKTX-101 with FDA interactions in H1 2026 and aims for IND/CTA submission end-2026/early-2027.
Akari Therapeutics (Nasdaq: AKTX) released a CEO Corner featuring CEO Abizer Gaslightwala summarizing 2025 progress and steps toward a clinical transition in 2026. The update highlights advancement of a novel ADC payload platform built on the proprietary PH1 spliceosome‑modulating payload, described as having a dual mechanism of direct tumor cytotoxicity plus immune activation and a compelling preclinical efficacy and safety profile. In 2025 the company announced a strategic manufacturing partnership with WuXi Biologics and began CMC and pre‑filing activities to support clinical readiness. Akari plans to initiate a First‑in‑Human trial as early as the end of 2026.
Akari Therapeutics (Nasdaq: AKTX) will present in person at the 2026 Biotech Showcase in San Francisco on Tuesday, January 13, 2026 at 9:30 AM PST in Yosemite A (Ballroom Level).
Abizer Gaslightwala, President and CEO, will overview Akari’s ADC platform, strategic priorities and key milestones for 2026. Management will also be available for in-person one-on-one meetings with registered, qualified investors during the conference running January 12–14, 2026.
Akari Therapeutics (Nasdaq: AKTX) issued its 2025 end-of-year letter outlining progress advancing antibody drug conjugates (ADCs) built on its proprietary PH1 payload, a spliceosome-modulating mechanism. Key 2025 milestones include: initiation of GMP manufacturing with WuXi XDC to support clinical supply, filing three new patents on the PH1 payload in H2 2025, preclinical activity of lead ADC AKTX-101 across pancreatic (KRAS), urothelial, gastric and AR-V7 prostate models, and differentiated safety in non-human primates. Akari plans regulatory interactions and aims to submit IND/CTA enabling a Phase 1 start in late 2026 or early 2027, subject to regulatory clearance.
Akari Therapeutics (Nasdaq: AKTX) has initiated GMP manufacturing for its lead ADC program, AKTX-101, selecting WuXi XDC as exclusive CDMO partner to perform IND-enabling work.
AKTX-101 uses Akari’s proprietary PH1 payload, described as an RNA-splicing modulator combining cytotoxic and immuno-oncology mechanisms. Akari expects this GMP material to support a Phase 1 first-in-human study planned for late 2026 or early 2027, subject to regulatory clearance.
Akari Therapeutics (NASDAQ: AKTX) released a Virtual Investor “What This Means” segment on Dec. 18, 2025 featuring President and CEO Abizer Gaslightwala.
The video covers Akari’s spliceosome-modulating payload PH1, new preclinical data for lead ADC AKTX-101 in hard-to-treat KRAS‑mutant pancreatic cancer, and the company’s plan to advance AKTX-101 into clinical testing by late 2026/early 2027. The segment is available to watch online.
Akari Therapeutics (Nasdaq: AKTX) announced a financing expected to raise approximately $5.0 million through a registered direct offering and concurrent private placement of a total of 12,607,487 ADSs (plus matching unregistered warrants).
The registered direct portion comprises 10,043,774 ADSs and Series G warrants at a combined price of $0.3883 per ADS and warrant; the private placement covers 2,563,713 pre-funded warrants and warrants at a combined price of $0.4041. Existing note holders will convert ~$2.50 million of debt into pre-funded warrants and warrants. More than $1 million of new cash comes from directors, officers and management. Proceeds will fund R&D, working capital and general corporate purposes; closing expected on or about Dec 17, 2025.
Akari Therapeutics (Nasdaq: AKTX) reported preclinical data showing its Trop2-targeting ADC AKTX-101 has single-digit nanomolar cytotoxic potency in K-Ras G12V pancreatic ductal adenocarcinoma (PDAC) cell lines and outperformed daraxonrasib in multiple PDAC cell lines.
The release notes Trop2 is highly expressed in K-Ras mutated PDAC, AKTX-101 carries a spliceosome-modulating payload PH1, and the company expects a first-in-human trial in late 2026 with preliminary safety and efficacy results in 2027.
FAQ
What is the current stock price of Akari Therapeutics Plc (AKTX)?
What is the market cap of Akari Therapeutics Plc (AKTX)?
